Ozempic, the quasi-weight-loss drug, is shaking up everything from snacks to seats

Ozempic has become more in demand as its name started cropping up in other companies' earnings reports.

What's the key learning?

Snack food brands have spoken about Ozempic's potential impact on their sales, and financial analysts claim that airlines could save a lot in fuel in average passenger weight falls.
The impact of Ozempic is reaching far and wide, beyond just the health sector.
It looks like many industries will have to start rethinking their strategies in response to Ozempic's boom.

👉 Background: Ozempic is the diabetes drug created by Danish company Novo Nordisk, which has also become popular with people wanting to lose weight. In fact, over 9 million prescriptions were written for Ozempic and similar drugs in just the last three months of 2022.

👉 What happened: Now, Ozempic has become more in demand than a date with Harry Styles as the drug's name has started cropping up in other companies' earnings reports:

Snack food brands have spoken about the potential impact of Ozempic's boom on their sales.
Financial analysts are saying that airlines could save tens of millions of dollars in fuel if average passenger weight falls.

👉 What else: It looks like many industries will have to start rethinking their strategies in response to this viral drug.

What's the key learning?

💡Breakthrough healthcare has ripple-effects for other industries. The impact of Ozempic is reaching far and wide, beyond just the health sector.

💡For instance, when wearable health monitors like Apple watches and Fitbits become popular, they didn't just impact health services and tech companies, but also the insurance sector.

💡 Another example is the digitisation of medical records, which boosted the cybersecurity industry and opened up a new market for them.

‍

Disclaimer: Flux Technologies Pty Ltd (ABN 86 634 507 172) is an authorised representative (Representative No. 1283166) of Mozo Pty Ltd who is the holder of AFSL No. 328141. We also provide general advice on credit products under our own Australian Credit Licence No. 530103. The product information presented does not constitute an offer and we are not recommending or suggesting any particular product. Any product advice presented is of a general nature only, and is not to be taken as any sort of advice as it has not taken into account your personal circumstances, objectives, financial situation or needs. Flux may not cover all products available to you. Check out our Credit Guide and Financial Services Guide for more information.

All information contained in the Flux app, www.flux.finance, www.joinflux.com, app.flux.finance and any podcast of Flux Media Pty Ltd (ABN 27 639 804 345) is for education and entertainment purposes only. It is not intended as a substitute for professional financial, legal or tax advice. Flux Media Pty Ltd is the owner of the registered trade mark, 'What the Flux'. While we do our best to provide accurate information on the podcast, we accept no responsibility for any inaccuracies that may be communicated.

Ozempic, the quasi-weight-loss drug, is shaking up everything from snacks to seats

What's the key learning?

What's the key learning?

Ready to win at money?

Become smarter in just 3 minutes! ⏱️